Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis

L. Ranek*, K. Dalhoff, H. Enghusen Poulsen, K. Brøsen, H. Flachs, S. Loft, P. Wantzin

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

To test the hypothesis that halothane hepatitis is caused by a combination of altered drug metabolism and an immunoallergic disposition, the metabolism of antipyrine, metronidazole, sparteine, phenytoin, and racemic R- and S-mephenytoin was investigated in seven subjects with previous halothane hepatitis. The HLA tissue types and the complement C3 phenotypes were also determined. The metabolism of antipyrine and metronidazole was within normal range in all subjects, and they were all fast or extensive metabolizers of sparteine, mephenytoin, and phenytoin. HLA tissue types were unremarkable. Five of the seven subjects had complement C3 phenotypes F or FS. In the general population phenotype S is the most common, but the difference in complement C3 phenotypes is not statistically significant (p = 0.07). We conclude, although in a limited number of patients, that subjects with previous halothane hepatitis do not appear to be different from controls with regard to drug metabolism and HLA tissue type. The possibility of a higher frequency of complement C3 phenotype F and FS needs further investigation.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Gastroenterology
Vol/bind28
Udgave nummer8
Sider (fra-til)677-680
Antal sider4
ISSN0036-5521
DOI
StatusUdgivet - 1. jan. 1993

Fingeraftryk Dyk ned i forskningsemnerne om 'Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis'. Sammen danner de et unikt fingeraftryk.

Citationsformater